Direct Answer
BPC-157 is a synthetic pentadecapeptide based on a sequence reported in human gastric juice. Published research is largely preclinical (in vitro and animal models); studies indicate possible roles in soft-tissue and gastrointestinal repair. It is a research chemical and is not approved for human use. As of June 2026 it sits in a regulatory gray zone: it was removed from the FDA 503A Category 2 bulk-substances list in April 2026 but not added to Category 1, and it remains not FDA-approved.
Summary Table
Evidence Level
Preclinical
Key Information
Classification
Key Takeaways
- BPC-157 is studied mainly in laboratory and animal models
- Human clinical evidence is limited
- It is a research chemical not approved for human use
Scientific Overview
In Plain English
BPC-157 is a lab-made peptide based on a fragment of a protein found in stomach fluid. Most of what is known comes from cell and animal studies, which suggest it may influence tissue-repair processes. It has not been approved by regulators for use in people, and large human studies are lacking.
Scientific Details
BPC-157 is a stable gastric pentadecapeptide investigated in rodent models of tendon, muscle, ligament, nerve, and gastrointestinal injury. Review literature describes signaling associated with angiogenesis and growth-factor pathways. The available evidence is predominantly preclinical, and controlled human outcome data are limited.
How It Works
In animal and in vitro studies, BPC-157 has been associated with angiogenic and cytoprotective signaling, including pathways linked to vascular endothelial growth factor and nitric oxide. These mechanisms are characterized mainly in laboratory models and have not been confirmed in controlled human studies.
Mechanism of Action
Angiogenic signaling
animal
In preclinical models, BPC-157 has been associated with formation of new blood vessels relevant to tissue repair.
Cytoprotection
animal
Animal studies describe protective effects on gastrointestinal and other tissues under injury conditions.
Evidence Level
Human Evidence
Controlled human evidence is limited; a related formulation (PL 14736) was explored for inflammatory bowel conditions, but robust human outcome data for BPC-157 are lacking.
Animal Evidence
Most evidence comes from rodent models of tendon, muscle, ligament, nerve, and gastrointestinal injury.
Cell Evidence
In vitro studies describe effects on cell migration and growth-factor-related signaling.
Limitations
The literature is predominantly preclinical and often from a small number of research groups; large, independent human studies are not available.
Why This Grade
Graded preclinical: the cited evidence is review-level literature summarizing rodent and in vitro models of musculoskeletal and gastrointestinal repair — no human study is cited. The literature is predominantly preclinical and often from a small number of research groups, and large, independent human studies are not available, so no controlled human outcome evidence supports the grade.
Frequently Asked Questions
How is BPC-157 thought to work?
In preclinical models, BPC-157 has been associated with angiogenic signaling (the formation of new blood vessels relevant to tissue repair) and cytoprotection (protective effects on gastrointestinal and other tissues under injury conditions). These are animal- and cell-level findings, not established human mechanisms.
Is BPC-157 safe?
There is not enough human data to consider BPC-157 established as safe. Published research is largely preclinical (laboratory and animal models), and large, independent human studies are not available — so reliable human safety data simply do not exist. It is a research chemical that is not approved for human use; as of 2026 it sits in a regulatory gray zone (removed from the FDA 503A Category 2 bulk-substances list in April 2026, not added to Category 1, and not FDA-approved). The absence of documented side effects in this entry reflects the lack of human study, not evidence that it is safe.
What is the evidence behind BPC-157?
It is preclinical. Most evidence comes from rodent models of tendon, muscle, ligament, nerve, and gastrointestinal injury, plus in vitro studies of cell migration and growth-factor-related signaling. Controlled human evidence is limited, and the literature often comes from a small number of research groups, so independent human confirmation is lacking.
Is BPC-157 approved or legal?
No. BPC-157 is not FDA-approved and is a research chemical not approved for human use. As of 2026 it sits in a regulatory gray zone: it was removed from the FDA 503A Category 2 bulk-substances list in April 2026 but not added to Category 1, and it remains not FDA-approved.
References
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research.Reviewdoi:10.1007/s00441-019-03016-8 →
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology.Reviewdoi:10.3389/fphar.2021.627533 →
- Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research.Reviewdoi:10.4103/1673-5374.320969 →
Alternative Names
- Body Protection Compound 157
- Pentadecapeptide BPC 157
- PL 14736
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals not approved for human use. Consult a licensed healthcare provider. This entry does not assert that BPC-157 is safe or beneficial in humans and is not a recommendation to use it.
This page summarizes published research and is for informational purposes only; it is not medical advice.